Hostname: page-component-586b7cd67f-rdxmf Total loading time: 0 Render date: 2024-11-28T13:51:26.000Z Has data issue: false hasContentIssue false
  • English
  • Français

Effects of aripiprazole long-acting two-injection start in patients diagnosed with schizophrenia in Huelva (Spain)

Published online by Cambridge University Press:  19 July 2023

A. Moleon ,
L. Duque  and
M. Martin-Bejarano
A. Moleon*
Affiliation:
Hospital Universitario Virgen del Rocio Instituto Andaluz de Salud Cerebral, Sevilla
L. Duque
Affiliation:
Hospital Universitario Juan Ramón Jimenez, Huelva
M. Martin-Bejarano
Affiliation:
Instituto Andaluz de Salud Cerebral, Sevilla Hospital Universitario 12 de Octubre, Madrid, Spain
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Improving outcomes in schizophrenia generally involves an improvement in drug adherence. Aripiprazole two-injection start (TIS) is the newest option of available on the market, with limited data on its effects.

Objectives

It was our goal to evaluate whether TIS has an effect on hospitalization rates, persistence and adverse events in patients with schizophrenia.

Methods

This 12-months cross-sectional study included 32 patients suffering from schizophrenia (mean age 33.6 years; 22 males). We collected sociodemographic data on all individuals, hospitalization rates, persistence, use of neuroleptic drugs as well as adverse events.

Results

Before starting TIS, the mean in terms of number of hospitalizations was 5.6, emergency department visits 8.7 and hospitalization days 12. After TIS, hospitalization rates was 22%, persistence 81%, adverse events were present in 3% of the patients and only 9% needed concomitant treatment with neuroleptic drugs.

Conclusions

The findings imply that TIS should be considered a first-line treatment choice for schizophrenic patients. It results in a decrease in the use of hospital services, which might ease the socioeconomic healthcare burden.

Disclosure of Interest

None Declared

Type
Abstract
Information
European Psychiatry , Volume 66 , Special Issue S1: Abstracts of the 31st European Congress of Psychiatry , March 2023 , pp. S1044
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2023. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.